Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021

OBJECTIVES: On 21 December 2020 the European Commission granted conditional marketing authorisation in the European Union for the anti-COVID-19 mRNA vaccine Bnt162b2 (Comirnaty, Pfizer/BioNTech). The main endpoint of this epidemiological, observational, prospective and monocentric study was to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Ossato, Andrea, Tessari, Roberto, Trabucchi, Carlotta, Zuppini, Teresa, Realdon, Nicola, Marchesini, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318724/
https://www.ncbi.nlm.nih.gov/pubmed/34315774
http://dx.doi.org/10.1136/ejhpharm-2021-002933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318724/
https://www.ncbi.nlm.nih.gov/pubmed/34315774
http://dx.doi.org/10.1136/ejhpharm-2021-002933

Ejemplares similares